In Vivo Gene Editing Market Size, Share & Trends Analysis by Editing Technology, Product & Service, Application (Genetic Disorders: Rare/Inherited; Oncology; Infectious; Cardiovascular; Neurological), and End User - Global Opportunity Analysis & Industry Forecast (2026-2036)

What is the Global In Vivo Gene Editing Market Size?

The global in vivo gene editing market was valued at USD 3.4 billion in 2025. This market is expected to reach USD 22.6 billion by 2036 from an estimated USD 4.8 billion in 2026, growing at a CAGR of 16.8% during the forecast period 2026-2036. According to Intellia Therapeutics' 2025 annual report, the company's NTLA-2001, a CRISPR-based in vivo therapy for transthyretin amyloidosis, achieved a mean 93% reduction in serum TTR protein in its Phase 1 clinical trial, a level of target knockdown comparable to the approved siRNA drug inclisiran and demonstrating for the first time that a single-dose CRISPR in vivo editing therapy can achieve durable and clinically meaningful gene knockdown in human patients without the need for ex vivo cell manipulation.

Key Highlights: Global In Vivo Gene Editing Market

• The global in vivo gene editing market is projected to reach USD 22.6 billion by 2036.
• The market is expected to grow at a CAGR of 16.8% during the forecast period 2026-2036.
• The global in vivo gene editing market was valued at USD 3.4 billion in 2025 and is estimated to reach USD 4.8 billion in 2026.
• North America is expected to dominate the global in vivo gene editing market with the largest market share in 2026, while Asia-Pacific is projected to register the highest CAGR during the forecast period.
• By editing technology, the CRISPR-based editing segment is expected to hold the largest share of the market in 2026, while the prime editing segment is projected to register the highest CAGR during the forecast period, as noted in the original TOC.
• By delivery system, the viral vectors (AAV) segment is expected to hold the largest share in 2026, while the non-viral (LNP) segment is projected to register the highest CAGR during the forecast period.
• By product and service, the therapeutics (clinical-stage) segment is expected to hold the largest share in 2026, while the platforms and technologies segment is projected to register the highest CAGR during the forecast period.
• By development stage, the clinical stage segment is expected to hold the largest share in 2026 with the fastest advancement toward Phase II and III transitions during the forecast period.
• By application, the genetic disorders segment, labeled the largest segment in the TOC, is expected to hold the largest share in 2026, while the cardiovascular diseases segment is projected to register the highest CAGR during the forecast period.
• By end user, the biopharmaceutical companies segment is expected to hold the largest share in 2026, while the biotechnology companies segment is projected to register the highest CAGR during the forecast period.

Market Overview and Insights

Click here to: Get Free Sample Pages of this Report 

In vivo gene editing involves delivering gene editing tools directly into a living patient's body. The tools travel to target cells and make precise changes to the genome without removing and editing cells outside the body. This sets in vivo methods apart from ex vivo gene editing, which requires collecting patient or donor cells, manipulating them in a lab, and reinfusing them. The in vivo method can potentially treat a much wider range of diseases because many tissues and organs that need gene editing for therapeutic benefits, like the liver, heart, muscle, and central nervous system, are not easily accessible for ex vivo cell collection and return. The editing tools usually come in an adeno-associated virus vector or are packaged in a lipid nanoparticle. They are given through intravenous injection or direct tissue injection, allowing them to reach target cells and deliver the CRISPR components or other editing enzymes needed for the desired genomic change. 

The market entered a new phase of commercial growth in November 2023 when the FDA and UK MHRA approved Casgevy, the CRISPR Therapeutics and Vertex Pharmaceuticals gene editing therapy for sickle cell disease and beta-thalassemia. This made it the world's first approved CRISPR medicine. Although Casgevy uses ex vivo rather than in vivo editing, its approval confirmed CRISPR as a clinically and commercially accepted gene editing technology. It also created the regulatory and commercial framework that in vivo CRISPR programs are now using. According to Vertex Pharmaceuticals' 2025 annual report, Casgevy launched commercially in the U.S. and UK after its approvals, showing that gene editing therapies can successfully move from development to approval and patient access. Intellia Therapeutics' 2025 investor communications reported that its NTLA-2001 TTR amyloidosis in vivo CRISPR program achieved a 93% mean serum TTR reduction in Phase 1. Enrollment for Phase 3 is ongoing, making it the most advanced true in vivo CRISPR treatment. 

The LNP delivery revolution, which began with COVID mRNA vaccines, has been strongly supported by Intellia and Alnylam programs that showcase liver-targeted LNP delivery of CRISPR components with high efficiency and acceptable safety. This technology is crucial for in vivo gene editing. LNP delivery offers significant advantages over AAV delivery for liver-targeted applications. LNPs can be produced at scale without the immune response issues linked to AAV capsids. This allows for re-dosing if editing does not fully succeed or if a patient is not a suitable AAV candidate due to prior immune exposure. Alnylam Pharmaceuticals' 2025 annual report states that the company is applying its extensive experience with LNP liver targeting for siRNA delivery to support LNP-CRISPR programs in collaboration with Regeneron and other partners, validating the LNP platform for delivering in vivo gene editing tools.

Global In Vivo Gene Editing Market: Key Findings

What are the Key Trends in the Global In Vivo Gene Editing Market?

Intellia NTLA-2001 Phase 3 Enrollment Defining the Clinical Standard for In Vivo CRISPR

Defining the Clinical Standard for In Vivo CRISPR 

Intellia Therapeutics’ NTLA-2001 program for transthyretin amyloidosis is the most clinically advanced in vivo CRISPR treatment. It sets the standards for clinical, manufacturing, and regulatory processes for future in vivo CRISPR programs. NTLA-2001 uses a lipid nanoparticle formulation to deliver a CRISPR system that includes a guide RNA targeting the TTR gene and Cas9 mRNA directly into liver cells. This results in a single edit that effectively knocks out TTR protein production. Phase 1 data, updated at major cardiology and genetics conferences in 2024, showed a mean 93% reduction in serum TTR protein. This reduction lasted over 12 months, indicating that the editing was durable. According to Intellia's 2025 annual report, the company started Phase 3 enrollment for NTLA-2001 in TTR cardiomyopathy, focusing on patients with significant medical need and no effective treatment.

The commercial impact of NTLA-2001’s clinical success goes beyond the TTR amyloidosis indication. TTR cardiomyopathy affects an estimated 250,000 to 500,000 patients in the United States, based on 2025 data from the American College of Cardiology. This represents a significant commercial opportunity for a gene editing therapy. Intellia's 2025 annual report revealed a partnership with Regeneron, which provides Intellia with resources for its pipeline development. In return, Regeneron gets access to Intellia's LNP in vivo CRISPR delivery technology for other programs. The success of the NTLA-2001 program has validated the LNP delivery platform for in vivo CRISPR. This opens the door for applying the same technology to other liver-related diseases beyond TTR.

Verve Therapeutics Advancing In Vivo Base Editing for Cardiovascular Risk Reduction

Verve Therapeutics is developing in vivo base editing therapies that make precise single-letter changes to cardiovascular disease genes in the liver. This approach aims to permanently lower cardiovascular risk and targets the leading global cause of death, rather than focusing on rare genetic diseases like many previous gene editing programs. Verve’s VERVE-101 program uses a base editor delivered by lipid nanoparticles to change adenine to guanine in the PCSK9 gene in liver cells. This change alters PCSK9 from a functional protein to a non-functional variant, permanently reducing LDL cholesterol. This process is similar to what happens in individuals with loss-of-function PCSK9 mutations, who have low lifetime LDL levels and reduced cardiovascular disease risk.

According to Verve's 2025 investor updates, VERVE-101 achieved LDL cholesterol reductions between 39% and 55% at higher doses during its Phase 1b HEART-1 trial. The company considered its safety profile acceptable for this indication. Verve announced that it would advance VERVE-102, a newer, optimized base editor LNP formulation with better liver targeting, into clinical trials in 2025. If successful, the cardiovascular application of in vivo base editing could be commercially transformative. The population with heterozygous familial hypercholesterolemia and other high-risk cardiovascular diseases includes tens of millions of people worldwide, which represents a much larger market than any rare genetic disorder, offering a significant commercial opportunity for in vivo gene editing.

Prime Editing Emerging as the Next Frontier of In Vivo Precision Correction

Prime editing was invented by Professor David Liu and his team at the Broad Institute and Harvard University. This technology is licensed to Prime Medicine for therapeutic development. It is the most precise and versatile gene editing method available today. It can make all 12 types of single-base transitions and transversions, as well as small insertions and deletions, without causing double-strand DNA breaks. The lack of these breaks, which can lead to chromosomal translocations and other unexpected genome changes, gives prime editing a safety edge over CRISPR nuclease methods where precision is critical. Prime Medicine, which is commercializing prime editing for therapeutic use, announced that it started its first clinical trials in 2024 according to its 2025 investor updates. This moves prime editing into the clinical development phase for the first time.

The TOC's designation of prime editing as the fastest-growing technology area shows that both the scientific community and the industry recognize its potential. Prime editing's ability to make precise corrections instead of just gene knockouts broadens the types of genetic diseases that in vivo gene editing can tackle. Many inherited diseases, such as phenylketonuria and Wilson's disease, are caused by specific point mutations. These require precise corrections rather than destructive knockouts for the best therapeutic results. Prime editing's ability to insert the correct base sequence at the mutation site makes it particularly useful for restoring function in these cases. A publication in Nature Medicine in 2025 from the Liu laboratory and Prime Medicine scientists reported that next-generation prime editor designs showed significantly improved editing efficiency in vivo in non-human primate liver models, giving preclinical support for advancing prime editing into clinical development for liver disease treatments.

Market Dynamics

Drivers

Advancements in CRISPR and Gene Editing Technologies

The rapid and ongoing improvement of CRISPR gene editing technologies is gradually tackling the safety, efficiency, and delivery issues that once limited in vivo gene editing to a few applications. The development of high-fidelity Cas9 variants significantly reduces off-target editing activity, as shown in multiple peer-reviewed studies. This addresses the main safety concern for clinical in vivo applications, where off-target edits in any of the billions of cells in a patient's liver, heart, or brain could potentially lead to harmful effects, including cancer. A 2025 review in Nature Biotechnology states that next-generation CRISPR tools, such as high-fidelity Cas9, base editors, and prime editors, show off-target editing rates that are many times lower than first-generation Cas9 in published comparisons. This level of precision is essential for clinically acceptable in vivo gene editing. The FDA's 2024 approval of Casgevy, the world's first CRISPR medicine, confirmed the agency's readiness to approve gene editing therapies when the safety and efficacy data are strong.

Growing Demand for Curative Therapies

The idea of a single-dose treatment that can permanently fix a genetic disease by editing the harmful mutation at the genomic level is one of the most exciting prospects in modern medicine. It has created strong demand from both clinical and patient communities for in vivo gene editing. Vertex Pharmaceuticals' 2025 annual report shows that Casgevy's launch for sickle cell disease proved that patients and healthcare systems are willing to pay high prices for potentially curative gene editing treatments. List prices exceed USD 2 million per treatment, which reflects the high lifetime costs of chronic management compared to a one-time curative edit. The approval of Casgevy, along with the success of gene replacement therapies like Zolgensma (for spinal muscular atrophy) at USD 2.1 million per dose and Hemgenix (for hemophilia B) at USD 3.5 million per dose, has set up the commercial and reimbursement framework for one-time curative genetic therapies that in vivo gene editing programs can build on.

Opportunities

Development of Novel Delivery Platforms

The development of better delivery platforms that can efficiently transport gene editing components to tissues other than the liver is the most important technical challenge and opportunity in the in vivo gene editing field. Current lipid nanoparticles (LNPs) primarily target the liver with high efficiency because they naturally accumulate there through the uptake of apolipoprotein-coated particles by hepatocytes. This focus makes liver diseases the immediate target for LNP-delivered in vivo editing, but it leaves tissues like muscle, the central nervous system, and lungs less accessible. Companies such as Precision BioSciences, ReCode Therapeutics, and Sana Biotechnology are creating targeted delivery methods. These include ionizable lipid nanoparticles with tissue-specific targeting ligands, engineered extracellular vesicles, and muscle-targeting AAV capsid variants. These advancements could broaden in vivo editing access to other tissues. A 2025 publication in Nature Biomedical Engineering suggests that engineered LNPs with selective organ targeting achieved over 90% specificity for the lung or spleen in preclinical models. This shows that organ-specific LNP delivery is technically feasible beyond just targeting the liver.

Integration with AI-driven Target Discovery

The use of AI in gene editing is speeding up the development of in vivo gene editing programs. AI models trained on large datasets of CRISPR guide RNA activity and off-target effects can predict on-target cutting efficiency and off-target risks of potential guide RNAs much better than traditional sequence-based rules. This allows researchers to find the best guides for new targets in days instead of weeks of experimental screening. According to Editas Medicine's 2025 research communications, the company is applying computational AI tools for guide RNA design, which significantly lower the experimental screening workload for new program development. Verve Therapeutics has revealed that it uses AI to optimize base editor configurations for its cardiovascular programs.

Editing Technology Insights

By Editing Technology: In 2026, CRISPR-based Editing to Hold the Largest Share

Based on editing technology, the global in vivo gene editing market is divided into CRISPR-based editing, base editing, prime editing, zinc finger nucleases, and TALENs. In 2026, the CRISPR-based editing segment is expected to hold the largest share of the global in vivo gene editing market. CRISPR-Cas9 and its variants are the leading gene editing platform in terms of clinical programs, research publications, and commercial investment. In November 2023, the FDA and UK MHRA approved Casgevy, the first CRISPR medicine. This made CRISPR the first gene editing technology to gain regulatory approval. Intellia's NTLA-2001 Phase 3 program for in vivo TTR editing represents the most advanced true in vivo CRISPR clinical program. The numerous CRISPR in vivo programs from Intellia, Editas, CRISPR Therapeutics, Caribou, and various academic-commercial partnerships make CRISPR the leading technology in terms of both program count and investment.

However, the prime editing segment is expected to show the highest growth rate during the forecast period. Prime Medicine will begin its first clinical trials in 2024, marking the entry of prime editing into the clinical phase. A 2025 publication in Nature Medicine will demonstrate significantly improved efficiency of prime editing in non-human primate liver, laying the groundwork for a wave of prime editing clinical programs. The unique ability of prime editing to accurately correct point mutations—rather than just disabling genes—makes it suitable for a wider range of genetic diseases than CRISPR knockouts alone.

Delivery System Insights

By Delivery System: In 2026, Viral Vectors (AAV) to Hold the Largest Share

Based on the delivery system, the global in vivo gene editing market is divided into viral vectors (AAV, lentiviral vectors, and other viral vectors) and non-viral delivery (LNPs, polymer-based systems, and physical methods). In 2026, the viral vectors segment, especially AAV, is expected to hold the largest share of the global in vivo gene editing market. AAV has been the go-to delivery tool for gene therapy for twenty years and has the most clinical data backing its safety and effectiveness for delivering genes to various tissues, including the liver, muscle, eye, and CNS. Approved gene therapy products like Luxturna (eye), Zolgensma (CNS/muscle), and Hemgenix (liver) are all based on AAV. This has set the regulatory and commercial groundwork for AAV delivery. Sangamo Therapeutics' early ZFN in vivo programs used AAV delivery, and several early CRISPR in vivo programs also use AAV vectors to transport CRISPR components to target tissues.

However, the non-viral delivery segment, especially LNPs, is expected to see the highest growth rate during the forecast period. The clinical success of LNP delivery for in vivo CRISPR, shown in Intellia's NTLA-2001 Phase 1 results with a 93% TTR knockdown, along with LNP's advantages in manufacturing scale compared to AAV, is leading to more investment in LNP-based in vivo gene editing delivery. Verve Therapeutics' VERVE-101 LNP base editing program and several other LNP-delivered programs are driving fast growth in LNP delivery for gene editing applications.

Product & Service Insights

By Product & Service: In 2026, Therapeutics (Clinical-stage) to Hold the Largest Share

Based on product and service, the global in vivo gene editing market is divided into therapeutics (clinical-stage and preclinical therapies), platforms and technologies (editing platforms and delivery platforms), and services (contract research and gene editing services). By 2026, the clinical-stage therapeutics segment is expected to hold the largest share of the global in vivo gene editing market. Clinical-stage in vivo gene editing programs are the most valuable assets in the market. They generate licensing deal payments, collaboration milestones, and revenues from clinical manufacturing services. Intellia's NTLA-2001 Phase 3 program, Verve's VERVE-101 and VERVE-102 cardiovascular programs, along with the growing group of Phase 1/2 in vivo editing programs from Editas, Sangamo, Beam, and others, represent a clinical-stage asset base with significant and increasing commercial value.

However, the platforms and technologies segment is expected to show the highest compound annual growth rate during the forecast period. The understanding that unique platform capabilities for guide RNA design, delivery system engineering, and manufacturing scale-up are the key long-term competitive advantages in the in vivo gene editing market is boosting investment in platform development and licensing. Prime Medicine's prime editing platform, Beam Therapeutics' base editing platform, and Intellia's LNP delivery platform are all generating licensing revenues as pharmaceutical companies seek access to these exclusive capabilities.

Development Stage Insights

By Development Stage: In 2026, Clinical Stage to Hold the Largest Share

Based on development stage, the global in vivo gene editing market is divided into three categories: discovery stage, preclinical stage, and clinical stage. By 2026, the clinical stage segment is expected to hold the largest share of the global in vivo gene editing market in terms of revenue. This segment stands out because clinical-stage program assets produce the most important transactions, such as milestone payments, licensing deals, and clinical manufacturing services. According to ClinicalTrials.gov's 2025 database, there are over 40 in vivo gene editing programs currently in active clinical trials. This number is more than double what it was three years ago. CRISPR-based, base editing, and prime editing programs are all moving forward to the clinical stage. The shift of programs from Phase 1 to Phase 2 and Phase 3 is the key trend in market advancement. Notably, Intellia's NTLA-2001 has entered Phase 3 according to its 2025 annual report.

The clinical stage segment is also set to experience the most significant progress throughout the forecast period. The current group of Phase 1 programs will provide the safety and efficacy data needed to support investment decisions for Phase 2 and Phase 3. Multiple programs from Intellia, Verve, Beam, and Prime Medicine are expected to move into later clinical stages during this forecast period.

Application Insights

By Application: In 2026, Genetic Disorders to Hold the Largest Share

Based on application, the global in vivo gene editing market is segmented into genetic disorders (rare genetic diseases and inherited disorders), oncology, infectious diseases, cardiovascular diseases, neurological disorders, and other applications. In 2026, the genetic disorders segment, labeled the largest segment in the original TOC, is expected to account for the largest share of the global in vivo gene editing market. Rare genetic diseases defined by single-gene mutations are the most scientifically tractable in vivo gene editing applications because the target gene and the desired genetic change are precisely defined, making guide RNA design straightforward and clinical endpoint selection clear. TTR amyloidosis, alpha-1 antitrypsin deficiency, and hereditary angioedema are among the rare disease targets for Intellia's pipeline, and the FDA's established regulatory pathway for gene editing in rare diseases provides a well-understood approval framework.

However, the cardiovascular diseases segment is projected to register the highest CAGR during the forecast period. Verve Therapeutics' VERVE-101 and VERVE-102 base editing programs targeting PCSK9 for LDL cholesterol reduction, combined with its VERVE-201 program targeting ANGPTL3 for triglyceride reduction, are advancing in vivo gene editing into cardiovascular disease, the world's largest disease category by mortality. The potential cardiovascular patient population for in vivo gene editing is many orders of magnitude larger than rare disease patient populations, and successful clinical validation in cardiovascular disease would represent the most commercially transformative expansion of in vivo gene editing beyond its current rare disease focus.

End User Insights

By End User: In 2026, Biopharmaceutical Companies to Hold the Largest Share

Based on the end user, the global in vivo gene editing market breaks down into biopharmaceutical companies, biotechnology companies, academic and research institutes, and CROs. In 2026, the biopharmaceutical companies segment is expected to hold the largest share of the market. Large pharmaceutical companies like Vertex Pharmaceuticals, Regeneron, Pfizer, and Novartis are investing in in vivo gene editing through internal programs, licensing deals, and direct acquisitions. Vertex's partnership with CRISPR Therapeutics led to the approved Casgevy product, which generates ongoing royalty revenue according to Vertex's 2025 annual report. This makes it the most commercially successful pharmaceutical company's involvement in gene editing. Regeneron's collaboration with Intellia, highlighted in various communications, gives Regeneron access to in vivo CRISPR editing for multiple targets. In exchange, Intellia receives development resources.

However, the biotechnology companies segment is expected to see the highest CAGR during the forecast period. Specialist in vivo gene editing companies, including Intellia, Verve, Beam, Prime Medicine, Editas, Sangamo, and Caribou, drive innovation in the market. They generate clinical data, validate delivery technologies, and build the evidence base that large pharmaceutical companies license. These specialist companies are increasing their revenues by progressing through clinical stages, forming partnership agreements, and licensing their platforms at above-average rates as their programs advance and their technology gains recognition.

Geographical Insights

In Vivo Gene Editing Market by Region: North America Leading by Share, Asia-Pacific by Growth

Based on geography, the global in vivo gene editing market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

In 2026, North America is expected to hold the largest share of the global in vivo gene editing market. The United States has the most advanced in vivo gene editing companies, such as Intellia Therapeutics, Verve Therapeutics, Beam Therapeutics, Prime Medicine, Editas Medicine, Sangamo Therapeutics, Precision BioSciences, and Caribou Biosciences. Together, these companies form the center for in vivo gene editing development. According to PhRMA's 2025 annual report, U.S. biopharmaceutical R&D investment reached a record of USD 104 billion in 2024. Gene editing and gene therapy programs are a fast-growing and valuable part of this investment. The FDA approved Casgevy in November 2023, marking the first CRISPR medicine per FDA press releases. This approval set the U.S. regulatory framework for gene editing therapy and showed that the FDA is willing to approve gene editing products with the right safety and efficacy data. The Broad Institute of MIT and Harvard holds important CRISPR patents and has licensed them to several gene editing companies. Meanwhile, the labs of Jennifer Doudna at UC Berkeley and David Liu at Harvard/Broad are key academic centers producing the science that supports in vivo gene editing companies. Vertex Pharmaceuticals' 2025 annual report confirms Casgevy's commercial launch in the U.S. and UK, providing the first commercial revenue reference for an approved gene editing therapy.

The Asia-Pacific in vivo gene editing market is set to grow at the fastest rate during the forecast period. China has built an active gene editing research and commercial ecosystem. Domestic companies like EdiGene, Correctsequence Therapeutics, and various university spin-outs are advancing CRISPR and base editing programs for genetic diseases common among Chinese patients. According to the National Medical Products Administration's 2024 guidance on gene editing therapies, which follows international ICH standards and creates domestic review pathways, China is developing the regulatory framework to evaluate and approve in vivo gene editing products at home. Japan's strong pharmaceutical industry and robust gene editing research programs at Osaka University and other major universities are aiding Asia-Pacific's growing in vivo gene editing landscape. South Korea and Singapore are also investing in gene editing research and development.

Key Players in the Global In Vivo Gene Editing Market

The in vivo gene editing market is served by specialist gene editing biotechnology companies with proprietary editing technology platforms and clinical programs, large pharmaceutical companies with significant gene editing collaborations and internal programs, delivery technology companies providing the viral vector and LNP platforms that enable in vivo editing, and contract research organizations supporting gene editing program development and manufacturing. Competition is based on editing precision and efficiency in vivo, delivery system tissue targeting capability and manufacturing scalability, clinical stage advancement and efficacy evidence, regulatory approval track record, and the breadth of therapeutic indication pipeline.

The report provides a comprehensive competitive analysis based on a thorough review of leading players' editing technology platform capabilities, delivery system expertise, clinical stage advancement, regulatory milestones, and recent strategic developments. Some of the key players operating in the global in vivo gene editing market include Intellia Therapeutics Inc. (U.S.), CRISPR Therapeutics AG (Switzerland/U.S.), Editas Medicine Inc. (U.S.), Beam Therapeutics Inc. (U.S.), Prime Medicine Inc. (U.S.), Sangamo Therapeutics Inc. (U.S.), Precision BioSciences Inc. (U.S.), Caribou Biosciences Inc. (U.S.), Verve Therapeutics Inc. (U.S.), Regeneron Pharmaceuticals Inc. (U.S.), Vertex Pharmaceuticals Incorporated (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), AstraZeneca plc (UK), and Takeda Pharmaceutical Company Limited (Japan), among others.

Key Questions Answered